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Abstract
Vascular smooth muscle cells (VSMCs) play important roles not only in the physiological 
functions of the blood vessels, such as vasoconstriction, vasodilatation and extracellular 
matrix production, but also in the pathogenesis of vascular diseases, particularly athero-
sclerosis and hypertension. VSMCs are mostly of mesodermal origin, although some are of 
neuroectodermal origin, for example, VSMCs present in the aorta and in blood vessels aris-
ing from the aortic arch. VSMCs of neuroectodermal origin are implicated in defects of car-
diovascular morphogenesis, such as bicuspid aortic valve, coarctation of the aorta, patent 
ductus arteriosus and tetralogy of Fallot. The origin, location in the vascular tree, gender, 
species, strain and age influence the phenotype of VSMCs and their propensity to migra-
tion and growth. In a healthy adult organism, VSMCs have a quiescent and differentiated 
contractile phenotype characterized by early markers (e.g., SM α-actin, SM22-α), intermedi-
ate markers (h-caldesmon, calponin) and late markers (SM myosins, smoothelin) of VSMC 
differentiation. However, after blood vessel injury, surgery or explantation in vitro, VSMCs 
undergo a phenotypic modulation to synthetic phenotype, which endows them with high 
activity in migration, growth and proteosynthesis. These features can lead to stenosis or to 
obliteration of the vascular lumen and impaired blood supply to various tissues and organs.
Keywords: blood vessels, smooth muscle cells, contractile phenotype, synthetic 
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1. Introduction
Vascular smooth muscle cells (VSMCs) are an important component of blood vessels. The cells 
are located in the medium part of a blood vessel, that is, tunica media, where they are oriented in 
a circle around the vascular lumen and form numerous layers. In medium vessels, there are up 
to 40 layers of VSMCs, and in large vessels, there are up to 60 layers. As the medium part of the 
blood vessel wall, the tunica media is located between the tunica intima and tunica adventitia, and 
is separated from these parts by the lamina elastica interna and the lamina elastica externa, respec-
tively. The tunica intima (also referred to as tunica interna) contains a semipermeable monolayer 
of endothelial cells and forms the luminal part of a blood vessel, contacting the blood. The tunica 
adventitia, that is, the exterior part of a blood vessel (also referred to as tunica externa), contains 
fibroblasts, nerves and, in bigger vessels, also small blood vessels supplying the vascular wall, 
called vasa vasorum. In addition, the tunica adventitia anchors blood vessels to the adjacent tissues 
(Figure 1) [1]. This structure is similar in arteries and in veins; in veins, the tunica media is usually 
thinner, due to the lower blood pressure in the venous bed, and the tunica intima in some veins 
contains valves in order to keep blood flowing in a single direction (Figure 2) [2]. The smallest 
blood vessels are capillaries, which lack the three classical layers of a blood vessel wall. They 
consist only of a fine tubular structure built of endothelial cells, which is surrounded by peri-
cytes, which are somewhat like VSMCs and are phenotypically similar to VSMCs (Figure 3) [3].
VSMCs play important roles in the physiological functioning of blood vessels and in patho-
logical changes in them. In healthy blood vessels of an adult organism, VSMCs ensure that the 
blood vessels contract and relax, and in this way, they make a marked contribution to the reg-
ulation of blood circulation. In healthy adult blood vessels, VSMCs are in a quiescent nonpro-
liferative phenotype, referred to as contractile phenotype. This phenotype is characterized by 
abundant contractile fibers containing VSMC-specific contractile proteins, such as α-isoform 
of actin and the SM-1 and SM-2 myosin heavy chain isoforms, and other specific proteins 
Figure 1. A scheme of the anatomy of an arterial wall. Available from [1].
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associated with the contractile apparatus [4–8]. Under pathological conditions accompanying 
the onset and development of vascular diseases, VSMCs undergo a process referred to as 
phenotypic modulation, that is, they switch from the contractile phenotype to the synthetic 
phenotype, characterized by a loss of contractile filaments and associated molecules, and by 
increased formation of organelles associated with proteosynthesis (Figure 4) [9]. VSMCs of 
Figure 2. A scheme of the anatomy of a venous wall. Available from [2].
Figure 3. A scheme of the anatomy of a capillary. Available from [3].
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synthetic phenotype are active in migration and growth. This can lead to intimal thickening, 
formation of atherosclerotic plaques, thickening of the blood vessel wall during hypertension, 
and finally to stenosis or full obliteration of the vascular lumen [4–6, 9–11]. Similar changes in 
VSMCs also occur after vascular surgery and when VSMCs are cultivated in vitro, particularly 
under conventional static conditions and in standard serum-supplemented media [6, 7, 12].
This chapter summarizes the most important knowledge on the role of VSMCs in the physi-
ological behavior and in pathological alterations of blood vessels, on the contractile and syn-
thetic phenotype of VSMC, and on the implication of these cells in developmental disorders 
of the cardiovascular system, atherosclerosis and hypertension. This chapter includes the 
author’s own experience in her studies of gender-related differences in the migration and 
proliferation of VSMCs, and in studying the role of VSMCs in vascular remodeling during 
hypoxic pulmonary hypertension.
2. Vascular smooth muscle cell origin and its role in vascular 
pathology
2.1. Sources of VSMCs
The VSMCs arise from two main sources: the mesoderm and the neuroectoderm, that is, 
the ectoderm of the neural crest. Most of the VSMCs in the vascular tree are of mesodermal 
origin, and are formed mainly from mesenchyme, that is, a type of connective tissue found 
mostly during the development of an embryo [13]; or from mesothelium via the epithelial-to-
mesenchymal transition [14].
VSMCs differentiated from neural crest cells reside in the cardiac outflow tract, the ascend-
ing aorta, the aortic arch, the proximal thoracic aorta, the brachiocephalic trunks, the com-
mon carotid arteries, the internal and external carotid arteries and subclavian arteries, and 
also in the blood vessels of the facial structures and the forebrain [15–17]. The pericytes in 
regions supplied by these vessels are also of neuroectodermal origin [18]. Neural crest cells 
also differentiate into adventitial fibroblasts. However, the endothelial cells of all the vessels 
are of mesodermal origin [15, 19]. In addition, the coronary and pulmonary arteries and the 
descending aorta remain devoid of neuroectodermal VSMCs and contain only mesodermal 
VSMCs, similarly as the remaining vessels in the body [20].
Figure 4. Transition between the contractile and synthetic phenotype in VSMC [9].
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The factors that regulate the differentiation of neural crest cells into VSMCs include the Notch 
and Hippo signaling pathways, fibronectin, transforming growth factor-β (TGF-β), Smad2, 
and myocardin-related transcription factor B.
The Notch plays a critical, cell-autonomous role in the differentiation of neural crest pre-
cursors into smooth muscle cells both in vitro and in vivo. Mutations in components of the 
Notch signaling pathway result in defects of the cardiac outflow tract [21]. For proper Notch 
signaling, Hippo signaling is required. Neural crest-specific deletion of the Hippo effectors 
Yap and Taz produces neural crest precursors that migrate normally, but fails to differentiate 
into VSMCs [22]. In addition, Notch signaling is regulated by fibronectin 1 (Fn1), which is 
synthesized by the neural crest cells (NCCs) and mediates the morphogenesis of the aortic 
arch artery. The Fn1 signals are delivered into NCCs through integrin α
5
β
1
 adhesion receptors 
and lead to the differentiation of NCCs into VSMCs [23].
TGF-β plays a controversial role in VSMC differentiation. On the one hand, TGF-β induces the 
differentiation of VSMCs from NCCs. This differentiation is mediated by Smad2, a transcrip-
tion factor which is required for TGF-β-induced nuclear translocation of myocardin-related 
transcription factor B (MRTFB). MRTFB enhanced the binding of Smad2 to a promoter of the 
expression of genes encoding differentiation markers of VSMCs [24, 25]. On the other hand, 
in mature VSMCs of neural crest origin, TGF-β increased the synthesis of DNA, which is 
known to be associated with a loss of differentiation markers in VSMCs. At the same time, 
TGF-β inhibited the growth of VSMCs of mesodermal origin. This dual effect of TGF-β was 
explained by the different composition of TGF-β receptors in VSMCs of different origin. In 
neuroectodermal VSMCs, subunit II is non-glycosylated, while in mesodermal VSMCs, sub-
unit II of this receptor is fully glycosylated [26].
2.2. The role of VSMC origin in developmental pathology
Proper differentiation of neural crest cells into VSMCs is required for normal cardiovascular 
morphogenesis. If this differentiation is defective, various cardiovascular disorders can occur, 
for example, bicuspid aortic valve, coarctation of the aorta, patent ductus arteriosus, tetralogy 
of Fallot, aneurysm of the thoracic aorta, and intracranial aneurysm.
Bicuspid aortic valve (BAV) is associated with the decreased expression of MYH11, the gene 
encoding the myosin heavy chain in VSMCs of neural crest origin, impaired contraction of 
these cells and decreased TGF-β signaling based on phosphorylation of SMAD2. In addi-
tion, patients with BAV are at higher risk of developing aneurysms of the thoracic aorta than 
patients with tricuspid aortic valve [27].
The major role in the pathogenesis of coarctation of the aorta in humans is attributed to 
deregulation of the Forkhead Box C1 (FOXC1) transcription factor or its downstream genes 
[28]. FOXC1 is also involved in the pathogenesis of ocular diseases, particularly glaucoma. 
FOXC1 dysfunction causes disruptions in basement membrane integrity and lower resistance 
of cells to cell death in response to oxidative stress [29, 30]. In addition, patients with BAV and 
coarctation of the aorta are more prone to developing an intracranial aneurysm [31].
Patent ductus arteriosus, that is, a temporary fetal vessel that bypasses the lungs by shunting 
the aortic arch to the pulmonary artery, can result from insufficient proliferation, differentiation 
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and contractility of a specific smooth muscle subpopulation that shares a common neural 
crest precursor with cardiovascular melanocytes [32].
Tetralogy of Fallot (TOF) is a serious congenital disorder characterized by a ventricular 
septal defect, overriding aorta, right ventricular outflow tract obstruction (i.e., pulmonary 
stenosis) and right ventricular hypertrophy. TOF has a polygenic origin, being caused by 
a combination of deleterious mutations in genes essential for apoptosis and cell growth, 
for the assembly of the sarcomere, and also for the neural crest and the secondary heart 
field, that is, the cellular basis of the right ventricle and its outflow tract. Numerous 
genetic abnormalities are associated with TOF. They include mutation of the gene encod-
ing myosin binding protein C3 (MYBPC3) [33], mutations and polymorphism of the gene 
encoding vascular endothelial growth factor (VEGF), which regulates vasculogenesis and 
angiogenesis [34, 35], mutation of the gene encoding Neuropilin1 (NRP1), a membrane 
co-receptor of VEGF [36], and mutation of the gene encoding Jagged1 (JAG1, also des-
ignated as CD339), that is, a cell surface protein interacting with receptors in the mam-
malian Notch signaling pathway [37], and also trisomy of chromosome 21, that is, Down’s 
syndrome [33].
3. Vascular smooth muscle cells in healthy adult vessels
In healthy adult blood vessels, the vast majority of VSMCs are in a quiescent non-proliferative 
phenotype. This phenotype is usually defined as contractile, while the phenotype of prolifer-
ating VSMCs has been widely referred to as synthetic. However, the population of quiescent 
nonproliferating VSMCs is highly heterogeneous, varying dynamically from primarily con-
tractile cells to synthetic cells specialized in extracellular matrix production [38]. In addition, 
the blood vessel wall contains abundant stem/progenitor cells, which are largely responsible 
for VSMC accumulation in the intima during vascular remodeling, such as neointimal hyper-
plasia and arteriosclerosis [10, 39–41]).
The degree of VSMC differentiation can be determined by the level of expression of spe-
cific markers of VSMC differentiation at mRNA and protein level. Markers of VSMC dif-
ferentiation have been divided into early, mid-term and late, according their appearance 
during embryonic development [42], during restoration of differentiated phenotype of 
VSMC [7] or during differentiation of stem cells toward VSMCs [43, 44]. For example, 
during the early stage of differentiation of embryonic stem cell-derived embryoid bodies, 
SM α-actin is the first to be detected, followed by myocardin, SM22-α and smooth muscle 
myosin heavy chain (SM-MHC). The expression of SM-α actin, myocardin, SM22-α and 
SM-MHC was found to begin on day 0, 8, 11, 13, respectively, during early embryonic 
vascular development [42].
Early markers of VSMC differentiation include SM α-actin, myocardin and SM22-α [7, 43, 45]. 
Mid-term markers are h-caldesmon and SM-calponin [46–50], although these markers have 
been designated in other studies as early markers [44]. Late markers are desmin, meta-vinculin, 
SM-1 and SM-2 isoforms of myosin heavy chain, and smoothelin [7, 43, 44]. Markers of VSMC 
differentiation, stained by immunofluorescence, are demonstrated in Figure 5 [8, 51–57].
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SM α-actin is the earliest known marker of VSMC differentiation, but its expression alone 
does not provide definitive evidence for a smooth muscle lineage [43]. SM α-actin is located 
in thin filaments of VSMCs, together with tropomyosin, troponin and calponin. Alpha-actin 
is the predominant isoform in the VSMCs of a healthy adult vessel. Other actin isoforms 
in VSMCs include β- and γ-actin, but they are minority components in adult physiological 
VSMCs, being localized predominantly in immature VSMCs during development or in dedif-
ferentiated VSMCs in diseased vessels [4, 5, 9, 58].
Myocardin is a transcription factor essential for VSMC-specific differentiation. It is a tran-
scriptional coactivator of the serum response factor involved in cell cycle regulation, apop-
tosis, cell growth and cell differentiation. Myocardin induces the expression of SM α-actin, 
Figure 5. Markers of early (A–C), intermediate (D, E) and late (F–I) differentiation of VSMCs. A–C, F–H: Green 
fluorescence; D, E, I: Red fluorescence. I: Co-localization of smoothelin with alpha-actin: Left: Smoothelin, center: 
α-actin, right: Merge. A: [51], B: [52], C: [53], D: [54], E: [55], F: [56], G [57], H: [51], I: [8].
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SM22-α, calponin and SM-MHC. Mice lacking myocardin die during embryogenesis from a 
lack of differentiated VSMCs. During supraphysiological mechanical load, for example dur-
ing hypertension and prolonged stretching of VSMCs in vitro, myocardin is translocated from 
the nuclei to the cytoplasm and is degraded by the proteasome, which led to phenotypic 
modulation of VSMCs toward the synthetic and proliferative phenotype [9, 59–62].
SM22-α is an actin-binding protein of the calponin family that is involved in calcium-inde-
pendent smooth muscle contraction [45, 63]. SM22-α interacts directly and co-localizes with 
F-actin, and it therefore participates in the organization of the actin cytoskeleton in differenti-
ated VSMCs. SM22-α facilitates the assembly of actin filaments into bundles, enhances the 
contractility and the mobility of VSMCs, and maintains the contractile phenotype in VSMCs 
[64]. Disruption of SM22-α is involved in osteochondrogenesis in arterial diseases and also in 
vascular inflammation [45, 65]. SM22-α attenuated vascular inflammation by suppressing the 
IKK-IκBα-NF-κB signaling cascades [65].
Caldesmon is a cytoskeletal protein interacting with actin, tropomyosin, myosin, calmodulin 
and phospholipids. Due to alternative splicing of one gene, calmodulin occurs in two isoforms, 
namely high molecular weight (89–93 kDa) caldesmon isoforms (h-caldesmon), and low 
molecular weight (59–63 kDa) caldesmon isoforms (l-caldesmon). H-caldesmon is present in 
adult and fully differentiated smooth muscle cells, while l-caldesmon is found in non-muscle 
cells and in de-differentiated smooth muscle cells. H-caldesmon is also a marker of tumors, for 
example of soft tissue tumors of the skin. All isoforms are potent inhibitors of the actin-tropo-
myosin activated myosin MgATPase. Smooth muscle caldesmon, together with tropomyosin, 
is a mediating factor for Ca2+-dependent inhibition of smooth muscle contraction [66, 67].
Calponin is another actin filament-associated regulatory protein expressed in smooth muscle 
cells and in many types of nonmuscle cells. It occurs in three isoforms, that is, calponin 1, 2 
and 3, encoded with three homologous genes, CNN1, CNN2 and CNN3, respectively. All three 
isoforms inhibit actin-activated myosin ATPase and stabilize the actin cytoskeleton. Calponin 1 
is specifically expressed in smooth muscle cells and plays a role in fine-tuning smooth muscle 
contractility. Similarly as in caldesmon, the interaction of calponin with actin inhibits actomyosin 
MgATPase activity. Calponin 2 is expressed both in smooth muscle cells and in nonmuscle cells, 
and it regulates multiple actin cytoskeleton-based functions. Calponin 3 participates in actin 
cytoskeleton-based activities in embryonic development, myogenesis and neuronal plasticity 
[68–70]. Another important role of calponin is its tumor-suppressing effect. The levels of calponin 
1 and 2 have been found to be decreased in tumor cells, and transfection of these cells with gene 
encoding calponin 1 reduced their growth and malignancy. The level of calponin 2 in the serum 
of patients can also be used as a biomarker of tumor diseases, for example, breast cancer [70, 71].
Desmin, together with vimentin, forms intermediate filaments in VSMCs. During the devel-
opment and specialization of cells toward smooth muscle cells, desmin replaces vimentin 
as the predominant component of intermediate filaments. Desmin is upregulated during 
differentiation of VSMCs from stem cells, for example, human bone marrow-derived mes-
enchymal stem cells (MSCs) [72] and also from embryonic mesothelial cells via epithelial-to-
mesenchymal transition [14]. Desmin and smooth muscle myosin were expressed together in 
the cells, and their acquisition appeared indicative of the terminal differentiation of smooth 
muscle [73]. However, the amount of desmin was found to be much lower in VSMCs than in 
smooth muscle cells of the digestive, respiratory, and urogenital tract, and also much lower 
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than the amount of vimentin in VSMCs [58]. For example, rat aortic smooth muscle cells 
contain 51% of vimentin alone-positive cells, 48% with both vimentin and desmin and 1% 
with desmin alone [4].
Meta-vinculin is a high-molecular form of vinculin, that is, a protein of the focal adhesion 
plaques associated with integrin adhesion receptors in cells [74]. Meta-vinculin and vincu-
lin are co-localized in focal adhesion plaques [75]. Together with SM-MHC, meta-vinculin is 
considered as a marker of well-differentiated contractile VSMCs [76, 77]). During phenotypic 
modulation of VSMCs, for example, in venous grafts used as aortocoronary bypasses [75], in 
human coronary arteries affected by arteriosclerosis [78] or during cultivation of VSMCs [75], 
the content of meta-vinculin in VSMCs decreases, and meta-vinculin can fully disappear from 
cells [75]. In cell culture conditions, the content of meta-vinculin in VSMCs can be reestab-
lished when the cells reach confluence [79]. During hypoxic pulmonary hypertension induced 
in newborn calves, proliferation occurred almost exclusively in the meta-vinculin-negative 
VSMC population rather than in the VSMC population expressing meta-vinculin [80].
SM-1 and SM-2 isoforms of myosin heavy chain (SM-MHC) are located in thick filaments of 
fully differentiated VSMCs. In intact adult rat thoracic aorta, the ratio of SM-1:SM-2 is 80:20 
both for mRNA and for protein [7]. VSMCs also contain the non-muscle (NM) isoform of 
myosin heavy chain, which is present, for example, in fibroblasts, macrophages, lymphocytes 
and platelets [81, 82]. The expression of myosin heavy chain isoforms in VSMCs is highly vari-
able. The same VSMC cell can contain all three isoforms of myosin heavy chain or only SM 
myosins [7, 83]. This leads to a functional diversity of VSMCs, which have a fast contractile 
gene program, giving rise to a phasic smooth muscle phenotype, or a slow contractile gene 
program, giving rise to a tonic smooth muscle phenotype [84]. During vascular diseases, such 
as atherosclerosis [74], after vascular surgery, for example, coronary angioplasty [85] or after 
explantation of VSMCs in vitro [7], the expression of SM-1 myosin, and particularly of SM-2 
myosin, decreases rapidly, while the content of NM myosin increases.
Smoothelin (SMTN) is a cytoskeletal protein present exclusively in contractile smooth mus-
cle cells. The SMTN family of proteins consists of two isoforms of SMTN, namely SMTN-A, 
SMTN-B, and the SMTN-like protein 1 (SMTNL1). The SMTN-A isoform is located predomi-
nantly in visceral smooth muscle cells, while the SMTN-B isoform is located in vascular 
smooth muscle cells, and SMTNL1 is located in both visceral and vascular smooth muscle 
cells. SMTN-A and SMTNL1 are associated with the contractile apparatus in VSMCs, and 
their main function is to increase the contraction potential of VSMCs, to contribute to vas-
cular adaptations in various physiological and pathological conditions, such as pregnancy, 
exercise training or hypertension and to contribute to the maintenance of the contractile 
phenotype [86, 87].
4. Vascular smooth muscle cells in vascular pathology
Typical examples of vascular diseases accompanied by vascular remodeling are atherosclero-
sis and hypertension. These two diseases have several common features, mainly thickening 
of the vessel wall and narrowing of the vascular lumen, which is due, among other reasons, to 
the activation of migration, growth and proteosynthesis in VSMCs.
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4.1. Atherosclerosis
The onset of atherosclerosis is usually associated with mechanical or biochemical damage 
to the endothelial cell layer. Mechanical damage occurs during hypertension or during vas-
cular surgery. Biochemical damage is due to the presence of various harmful compounds 
in the blood, for example, reactive oxygen species (ROS), nicotine or products of nonenzy-
matic glycation, and also due to elevated concentrations of originally physiological biomol-
ecules, such as glucose, cholesterol or homocysteine. Biochemically damaged endothelium 
becomes thrombogenic, permeable and immunogenic. Platelets adhering to the endothelium 
then release platelet-derived growth factor (PDGF), a potent mitogen and chemoattractant 
for VSMCs [88, 89]. The production of PDGF-like molecules and other growth factors, for 
example VEGF, is also activated in the VSMCs themselves [90]. Other examples of growth 
factors that can penetrate into the vascular wall from the blood through the damaged endo-
thelial barrier, and that can stimulate the proliferation of VSMCs, include epidermal growth 
factor (EGF), fibroblast growth factor (FGF) [91], nerve growth factor (NGF) [92], insulin-like 
growth factor-1 (IGF-1) [93] and TGF–β [11]. In addition to growth factors, other blood-borne 
molecules that can penetrate into the blood vessel wall can change the composition of its 
extracellular matrix (ECM) and can influence the behavior of VSMCs, include albumin, globu-
lins including immunoglobulins, hemoglobin, lipoproteins, fibrinogen, fibrin, thrombin and 
thrombospondin [94–98].
Damaged endothelium is also prone to inflammatory activation. Endothelial cells increase their 
expression of adhesion molecules of immunoglobulin and selectin families, namely intercellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and endothelial-leu-
cocyte adhesion molecule-1 (ELAM-1) [6, 11]. These molecules, present on the membrane of endo-
thelial cells, bind the cells of the immune system, namely leucocytes, lymphocytes, monocytes, 
macrophages and mast cells. These cells are then stimulated by chemotactic factors to migrate 
inside the vascular wall. The chemotactic factors include interleukins (e.g. interleukin-1), tumor 
necrosis factors (TNFs, e.g. TNF-α) and monocyte chemoattractant protein-1 (MCP-1), and are 
produced in VSMCs, endothelial cells and inflammatory cells [11, 99]. In addition, immunoglobu-
lin adhesion molecules, such as VCAM-1, can be expressed directly by VSMCs [100]. Another 
potent source of inflammatory cells penetrating inside the vascular wall is tunica adventitia, par-
ticularly its vasa vasorum [40, 101]. As concerns infiltration of the vascular wall with inflammatory 
cells, atherosclerosis has been considered as a specific type of inflammation [4, 102, 103]. In addi-
tion, the inflammatory cells produce proteolytic enzymes, such as chymase, tryptase and metal-
loproteases (MMPs, e.g. MMP-2, MMP-9 and MMP-13), which degrade the ECM and liberate the 
VSMCs from their proliferation control exerted by ECM [11, 104, 105]. The inflammatory cells also 
produce ROS, which can cause cell death in high concentrations. In low concentrations, however, 
they can stimulate phenotypic modulation and proliferation of VSMCs directly or indirectly by 
damage to the vascular ECM [11, 106]. Macrophages, like VSMCs, can proliferate within the dam-
aged vascular wall [4, 107] and can also store lipids and form so-called foam cells (Figure 6) [11].
Under all these pathological conditions, VSMCs in the damaged vascular wall undergo phe-
notypic modulation, migrate to the tunica intima and proliferate. The proliferation of VSMCs 
can be very massive and can lead to considerable stenosis or to full obliteration of the vas-
cular lumen. For this reason, early investigators of atherogenesis compared the proliferation 
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of VSMCs to the growth of tumor cells and considered atherosclerotic plaques as “benign 
tumors of VSMCs” [108, 109].
During phenotypic modulation, the late markers of VSMC differentiation are the first to be 
lost, while the early markers can persist even in migrating and proliferating cells. For example, 
smoothelin-B is the first smooth muscle cell marker that disappears when vascular tissues are 
compromised, for example, in atherosclerosis or restenosis [8]. Smoothelin was not detected in 
primary or long-term smooth muscle cell cultures, which simulate the pathological conditions 
in damaged blood vessels in vivo [86]. Similarly, in cultured VSMCs derived from the rat thoracic 
aorta and grown in 10% serum for 3–5 days to sub-confluence, the expression of SM-1 myosin 
at mRNA level decreased by 30% and the expression of SM-2 myosin at mRNA level decreased 
by 80%. At the protein level, SM-1 myosin was detectable at a reduced level in confluent cells, 
whereas SM-2 myosin was absent in confluent cells. Cultivation of confluent cells in serum-free 
media, that is under conditions used for restoration of the contractile phenotype, had little or no 
effect on SM-1 or SM-2 myosins at the mRNA level. In contrast, the level of SM α-actin, the earli-
est marker of VSMC differentiation, decreased both at the mRNA level and at the protein level. 
However, it did not fully disappear in these cells, and growth arrest by serum withdrawal or by 
high cell population density led to renewed SM α-actin expression in these cells [7]. In addition, 
phenotypically modulated VSMCs synthesize a spectrum of ECM molecules, which is altered 
quantitatively and qualitatively. For example, these VSMCs synthesize higher amounts of col-
lagen type I, III and V, elastin and glycosaminoglycan, particularly chondroitin sulfate A/C and 
dermatan sulfate [6, 110]. In addition, phenotypically-modulated VSMCs synthesize ECM mol-
ecules, which are typical for osteoblasts and are involved in matrix calcification, for example, 
osteopontin and osteonectin [111, 112]. These VSMCs also showed increased expression and 
Figure 6. A scheme of the process of atherogenesis [11].
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
239
DNA-binding activity of a transcription factor named Core binding factor alpha1 (Cbfa1) [111], 
expression of Runt-related transcription factor-2 (Runx2) [113], and increased expression and 
activity of alkaline phosphatase, an enzyme involved in matrix mineralization [111].
4.2. Hypertension
Two types of hypertension should be distinguished, namely systemic hypertension and 
pulmonary hypertension. Systemic hypertension can be a cause or a consequence of athero-
sclerosis, while pulmonary hypertension does not depend on the systemic blood pressure and 
has specific causes of its own, mainly pulmonary hypoxia.
Both types of hypertension include phenotypic modulation and proliferation of VSMCs, that 
is hyperplasia, which means an increasing number of VSMCs. In addition, systemic hyperten-
sion is characterized by the hypertrophy of VSMCs, that is an increase in VSMC volume. This 
hypertrophy is often associated with polyploidy, mainly tetraploidy and, to a lesser extent, also 
octoploidy. The polyploidization of VSMCs has been attributed to so-called “incomplete growth 
stimulation,” which is sufficient only for DNA synthesis and the onset of mitosis, but not for 
subsequent karyokinesis and cytokinesis. Incomplete growth stimulation has been attributed 
to an increased level of contractile agonists, such as angiotensin II, arginine vasopressin (also 
known as antidiuretic hormone), adrenaline, bradykinin and serotonin, which act as weak mito-
gens for VSMCs [114, 115]). Incomplete mitosis without karyokinesis and cytokinesis is referred 
to as endomitosis [116]. If only cytokinesis is absent, binucleated or multinucleated, VSMCs are 
formed. If only DNA synthesis occurs, without complete mitosis, the process of cell polyploidi-
zation is referred to as endoreduplication. The increase in volume and ploidy in VSMCs has 
often been referred to as “specific hypertrophy,” and has been considered by some investigators 
as a physiological response of VSMCs to mechanical loading during blood circulation, that is, as 
a certain type of VSMC differentiation. Polyploid VSMCs are more effective in synthesis of con-
tractile proteins and mechanically resistant ECM proteins, and occur even under physiological 
conditions. For example, the aorta of healthy young rats contains 8–10% of polyploid VSMCs. 
However, during hypertension and with increasing age, the number of polyploid VSMCs can 
reach several tens % [114, 116, 117]. For this reason, the polyploidy of VSMCs has been proposed 
as a biomarker of senescence [118]. In addition, contractile proteins, such as actin and myo-
sin, are not synthesized in proper isoforms typical for differentiated VSMCs. In other words, 
polyploidy of VSMCs appears to be associated with decreased-to-absent expression of muscle-
specific proteins [119]. Accordingly, the maximal force per cross-sectional area generated by the 
hypertrophic smooth muscle in aorta from hypertensive rats was lower than in normal rat aorta 
[120]. In addition, increased synthesis of ECM proteins (e.g., collagen III, fibronectin) can lead 
to increased stiffness of the blood vessel wall, which further worsens the hypertension [115].
The main cause of pulmonary hypertension is alveolar hypoxia, which is due to a lower concen-
tration of oxygen in the atmosphere, for example, at high altitudes [121] or in experimental isobaric 
or hypobaric hypoxic chambers [122–124]. Alveolar hypoxia also occurs during obstruction of air-
ways, for example, during bronchial asthma [125–126] and chronic obstructive pulmonary disease 
(including pulmonary emphysema) [121, 127, 128], during interstitial fibrosis, which hampers the 
diffusion of oxygen from the alveoles to the capillaries [121, 128], during sterile and microbial 
inflammations in lungs [124, 126], during thromboembolism in pulmonary arteries [129] and also 
during extrapulmonary diseases, such as liver diseases [130] and cardiac diseases [131]).
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Pulmonary hypertension leads to phenotypic modulation and hyperplasia of VSMCs [121, 
132, 133], but usually not to VSMC polyploidization. Surprisingly, the number of tetraploid 
VSMCs in pulmonary arteries even decreased, as revealed by flow cytometry of pulmonary 
arterial medial cells obtained from calves exposed to hypoxia in a hypobaric hypoxic chamber 
[122]. Tetraploid VSMCs were found in the pulmonary arteries of Eker rats, that is an animal 
model of somatic mutations in the tuberous sclerosis complex-2 (TSC2) gene [134].
Other factors associated with pulmonary hypertension include vasoconstriction [121, 131], 
damage to VSMCs by ROS [121], synthesis of ECM [132], degradation of ECM proteins by 
proteases [104, 105, 123], infiltration of the vascular wall with immunocompetent cells, par-
ticularly mast cells [104, 105], and inflammatory activation of VSMCs [132, 133, 135]. In addi-
tion, not only VSMCs in the tunica media, but also fibroblasts in the tunica adventitia migrate, 
proliferate and undergo inflammatory activation, and they therefore contribute to vascular 
remodeling [133, 136].
4.3. Other factors influencing the phenotype and proliferation of VSMCs
The propensity of VSMCs to phenotypic modulation and activation of migration and prolif-
eration can also be influenced by their origin, their location in the vascular system, species, 
strain, breeding conditions, age and gender.
As mentioned earlier, VSMCs are of neuroectodermal and mesodermal origin. These two types 
of VSMCs respond in a different manner to various factors playing roles in the pathogenesis of 
vascular diseases acquired in adulthood, for example, atherosclerosis. For example, the tunica 
media of the aortic arch composed of VSMCs of neural crest origin calcified significantly earlier 
than the tunica media of the descending aorta composed of mesoderm-derived VSMCs [137]. 
Fluid shear stress, another factor contributing to the development of vascular diseases, inhib-
ited the proliferation of mesodermal VSMCs but induced the proliferation of neuroectodermal 
VSMCs by increasing the expression of cyclin D1 (which mediates cell cycle progression from 
the G1 phase to the DNA-replicative S phase), by downregulating the cell cycle inhibitor p21 
and by activating the Akt pathway in a manner dependent on phosphoinositide 3-kinase [138]. 
In addition, mesodermal VSMCs derived from avian embryonic vessels expressed about 10 
times more SM α-actin and tropoelastin than neuroectodermal VSMCs [139].
An example of regional differences in VSMC growth is the higher incidence of polyploid 
VSMCs in the aorta and in other big elastic arteries than in smaller muscular arteries, for exam-
ple, mesenteric arteries [114, 115]. A possible explanation is the lower mechanical load of big 
arteries, leading to relatively little damage to the endothelial barrier and lower permeability of 
this barrier for mitogens from blood. Another explanation is that elastin keeps the VSMCs in a 
contractile quiescent state, and these VSMCs are therefore less responsive to growth stimula-
tion and undergo incomplete mitosis [140, 141]. Other examples include higher resistance of 
human VSMCs from the internal mammary artery to dedifferentiation and induction of migra-
tion and proliferation in comparison with VSMCs from other arteries, particularly VSMCs 
from coronary arteries [142], and a higher propensity of human arterial VSMCs than of venous 
VSMCs to form atherosclerotic lesions [143]. In spite of this, phenotypic alterations to venous 
VSMCs appear to be critical for the development of primary varicose veins. The VSMCs of vari-
cose veins showed a lower expression of desmuslin, an intermediate filament protein, which 
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resulted in decreased expression of SM α-actin, SM-MHC and smoothelin, disassembly of actin 
stress fibers and increased levels of collagen synthesis and MMP-2 expression [144]. Phenotypic 
modulation, migration and proliferation of VSMC intima also occurs in vein grafts implanted in 
arterial position, for example, as an aortocoronary bypass. The VSMCs in vein grafts decreased 
their expression of myocardin, SM-1 and SM-2 myosins [61] and meta-vinculin [74]. Phenotypic 
modulation and proliferation of VSMCs in vein grafts can be attenuated by a perivascular drug 
delivery system releasing sirolimus and preventing distension of the vein grafts [145, 146], and 
also by transduction of VSMCs with microRNA-145-encoding plasmids [61].
However, it should be pointed out that, in addition to regional differences in the VSMC phe-
notype and growth, the VSMC population of the same vessel is highly heterogeneous, con-
taining a wide spectrum of VSMCs varying from primarily contractile phenotype to synthetic 
cells specialized in extracellular matrix production, and also less-differentiated progenitor 
cells [10, 38–41].
Species-specific differences have been found, for example, in the expression of isoforms of arginase, 
that is an enzyme that stimulates VSMC proliferation and collagen deposition, and thus implicated 
in the vascular damage during atherosclerosis and during systemic and pulmonary hypertension. 
Specifically, rat VSMCs expressed isoform I of arginase, while human VSMCs expressed only argi-
nase II [147]. Another example is a species-specific difference in VSMC-endothelial cell interaction. 
In co-culture with endothelial cells, the proliferation of VSMCs derived from human aorta was 
inhibited, while the proliferation of bovine aortic VSMCs was stimulated [148].
Strain-specific differences in VSMC growth have been studied mainly in rats. It was found 
that polyploidization of aortic VSMCs was the highest in the Wistar-Kyoto (WKY) strain of 
rats (i.e., normotensive inbred rats related to spontaneously hypertensive rats, SHR); it was 
intermediate in SHR (genetically hypertensive rat), and it was lowest in Sprague-Dawley 
rats (i.e., normotensive outbred rats) and in Fischer rats (i.e., normotensive inbred rats). 
Nonarterial cells (venous VSMCs and lung cells) from WKY and SHR remained essentially 
diploid, suggesting that polyploidization is also tissue-specific [149]. At the same time, the 
proliferation, that is hyperplasia, of VSMCs derived from the aorta of SHR rats was markedly 
higher than that found in aortic VSMCs from WKY rats [150]. The propensity of VSMCs to 
migration and proliferation can also be influenced by breeding conditions. In our earlier 
study, the migration and proliferation of cultured aortic VSMC derived from Wistar rats 
raised under conventional conditions was higher than in cells from Wistar rats raised under 
specific pathogen-free (SPF) conditions [151].
The phenotype and growth of VSMCs can also be influenced by the age of the organism. 
The proliferation activity of fetal and neonatal VSMCs is higher, and their differentiation 
status is physiologically lower, than in adult VSMCs [152, 153]. In adult organisms, increased 
age is associated mainly with negative factors affecting VSMCs, for example, oxidative dam-
age, DNA damage (including telomere attrition), mitochondrial dysfunction, apoptosis, pro-
inflammatory secretory phenotype associated with the loss of VSMC differentiation markers, 
such as SM α-actin and SM22-α, increased expression of transcription factors Msx2 and Runx2 
and of bone morphogenetic protein-2, that is markers of osteoblast transition of VSMCs, and 
increased sensitivity of β-adrenoceptors, which are implicated in the inhibition of cellular 
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proliferation [154–157]. These changes in VSMC behavior caused by donor age can be further 
magnified by proliferative aging of VSMCs during their cultivation in vitro [156].
Gender plays an important role in the propensity of VSMCs to migration and proliferation. It 
is generally known that estrogens decrease the proliferative activity of VSMCs, while androgens 
increase it. This is considered as the main cause of the higher incidence of cardiovascular diseases 
in male organisms. However, VSMCs from males proliferated faster even without the actual pres-
ence of sex hormones in the cell culture medium. For example, VSMCs isolated from the thoracic 
aorta of adult male rats migrated earlier from the explants and proliferated faster than their female 
counterparts [158, 159]. These differences were enhanced in a serum-free medium [160] and after 
repeated passaging of VSMCs [161], and were also apparent in newborn rats [162] and in both WKY 
rats and SHR rats [150]. These differences have been explained by prenatal synthesis of androgens 
initiated by the expression of specific genes in the SRY locus on the Y chromosome. Among others, 
androgens increase the sensitivity of VSMCs to adrenergic hormones, which persists throughout 
life, and also without the actual presence of physiological levels of androgens [163, 164].
5. Conclusion
Vascular smooth muscle cells (VSMCs) are physiological and the most numerous component of 
the arterial and venous wall, and they ensure vasoconstriction and vasodilatation and other func-
tions, such as synthesis of extracellular matrix. However, VSMCs are also implicated in vascular 
disorders, such as defects of cardiovascular morphogenesis, atherosclerosis, and systemic and pul-
monary hypertension. The VSMCs in healthy adult blood vessels are in the quiescent contractile 
state, characterized by specific markers of VSMC differentiation namely SM α-actin, myocardin 
and SM22-α (early markers), h-caldesmon and SM calponin (intermediate markers) and desmin, 
meta-vinculin, SM-1 and SM-2 isoforms of myosin heavy chain and smoothelin (late markers). 
However, in pathologically changed blood vessels, VSMCs lose their differentiation markers, acti-
vate migration and proliferation and increase proteosynthesis. This VSMC behavior can lead to 
remodeling of the vascular wall, including stenosis and obliteration of the vascular lumen.
Acknowledgements
This study was supported by the Czech Health Research Council, Ministry of Health of the Czech 
Republic (project No. 15-33018A). Further support was provided by BIOCEV – Biotechnology and 
Biomedicine Centre of the Academy of Sciences and Charles University (CZ.1.05/1.1.00.02.0109), 
a European Regional Development Fund project. Mr. Robin Healey (Czech Technical University 
in Prague) is gratefully acknowledged for his language revision of the manuscript.
Conflict of interest
The authors declare no conflict of interest.
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
243
Author details
Lucie Bacakova1,2*, Martina Travnickova1,2, Elena Filova1,2, Roman Matějka1,2, 
Jana Stepanovska1,2, Jana Musilkova1, Jana Zarubova1,2 and Martin Molitor3
*Address all correspondence to: lucie.bacakova@fgu.cas.cz
1 Department of Biomaterials and Tissue Engineering, Institute of Physiology of the Czech 
Academy of Sciences, Videnska, Prague, Czech Republic
2 Biotechnology and Biomedicine Center of the Academy of Sciences and Charles University 
in Vestec (BIOCEV), Prumyslova, Vestec, Czech Republic
3 Clinic of Plastic Surgery, Faculty Hospital Na Bulovce, Budinova, Prague, Czech Republic
References
[1] Presentation of Abdelaty Shawky, Assoc. Prof. of Pathology. Available from: http://slide-
player.com/slide/8073072/ [Accessed: 2017-02-19]
[2] Man Anatomy. Veins. Available from: https://www.mananatomy.com/basic-anatomy/
veins. [Accessed: 2017-02-19]
[3] Exam 1 Review: Chapter 19: Capillaries. Available from: http://www.apsubiology.org/ 
anatomy/2020/2020_Exam_Reviews/Exam_1/CH19_Capillaries.htm. [Accessed: 2017-02-19]
[4] Schwartz SM, Campbell GR, Campbell JH. Replication of smooth muscle cells in vascu-
lar disease. Circulation Research. 1986;58(4):427-444. DOI: 10.1161/01.RES.58.4.427
[5] Campbell GR, Campbell JH. The phenotypes of smooth muscle expressed in human 
atheroma. Annals of the New York Academy of Sciences. 1990;598:143-158. DOI: 10.1111/
j.1749-6632.1990.tb42286.x
[6] Campbell JH, Campbell GR. Smooth muscle phenotypic modulation--a personal expe-
rience. Arteriosclerosis, Thrombosis, and Vascular Biology. 2012;32(8):1784-1789. DOI: 
10.1161/ATVBAHA.111.243212
[7] Babij P, Kawamoto S, White S, Adelstein RS, Periasamy M. Differential expression of 
SM1 and SM2 myosin isoforms in cultured vascular smooth muscle. The American 
Journal of Physiology. 1992;262(3 Pt 1):C607-C613. DOI: 10.1152/ajpcell.1992.262.3.C607
[8] van Eys GJ, Niessen PM, Rensen SS. Smoothelin in vascular smooth muscle cells. Trends 
in Cardiovascular Medicine. 2007;17(1):26-30. DOI: 10.1016/j.tcm.2006.11.001
[9] Shinohara S, Shinohara S, Kihara T, Miyake J. Regulation of differentiated phenotypes 
of vascular smooth muscle cells, Chapter 14. In: Sugi H, editor. Current Basic and 
Pathological Approaches to the Function of Muscle Cells and Tissues - from Molecules 
to Humans. InTech; 2012. pp. 331-344. DOI: 10.5772/3003, ISBN 978-953-51-0679-1. 
Available from: https://www.intechopen.com/books/current-basic-and-pathological-
Muscle Cell and Tissue - Current Status of Research Field244
approaches-to-the-function-of-muscle-cells-and-tissues-from-molecules-to-humans/
regulation-of-differentiated-phenotypes-of-vascular-smooth-muscle-cells
[10] Wang G, Jacquet L, Karamariti E, Xu Q. Origin and differentiation of vascular smooth 
muscle cells. The Journal of Physiology. 2015;593(14):3013-3030. DOI: 10.1113/JP270033
[11] Saleh Al-Shehabi T, Iratni R, Eid AH. Anti-atherosclerotic plants which modulate the 
phenotype of vascular smooth muscle cells. Phytomedicine. 2016;23(11):1068-1081. DOI: 
10.1016/j.phymed.2015.10.016
[12] Skalli O, Bloom WS, Ropraz P, Azzarone B, Gabbiani G. Cytoskeletal remodeling of rat 
aortic smooth muscle cells in vitro: Relationships to culture conditions and analogies 
to in vivo situations. Journal of Submicroscopic Cytology. 1986;18(3):481-493. PMID: 
3528513
[13] Hungerford JE, Owens GK, Argraves WS, Little CD. Development of the aortic vessel wall 
as defined by vascular smooth muscle and extracellular matrix markers. Developmental 
Biology. 1996;178(2):375-392. DOI: 10.1006/dbio.1996.0225
[14] Lachaud CC, López-Beas J, Soria B, Hmadcha A. EGF-induced adipose tissue meso-
thelial cells undergo functional vascular smooth muscle differentiation. Cell Death & 
Disease. 2014;5:e1304. DOI: 10.1038/cddis.2014.271
[15] Etchevers HC, Vincent C, Le Douarin NM, Couly GF. The cephalic neural crest pro-
vides pericytes and smooth muscle cells to all blood vessels of the face and forebrain. 
Development. 2001;128(7):1059-1068. 11245571
[16] Sieber-Blum M. Cardiac neural crest stem cells. The Anatomical Record. Part A, 
Discoveries in Molecular, Cellular, and Evolutionary Biology. 2004;276(1):34-42. DOI: 
10.1002/ar.a.10132
[17] Sawada H, Rateri DL, Moorleghen JJ, Majesky MW, Daugherty A. Smooth muscle cells 
derived from second heart field and cardiac neural crest reside in spatially distinct 
domains in the media of the ascending aorta - brief report. Arteriosclerosis, Thrombosis, 
and Vascular Biology. 2017;37(9):1722-1726. DOI: 10.1161/ATVBAHA.117.309599
[18] Brown CB, Baldwin HS. Control neural crest contribution to the cardiovascular system. 
Advances in Experimental Medicine and Biology. 2006;589:134-154. DOI: 10.1007/978-0-387- 
46954-6_8
[19] Le Lièvre CS, Le Douarin NM. Mesenchymal derivatives of the neural crest: Analysis of 
chimaeric quail and chick embryos. Journal of Embryology and Experimental Morphology. 
1975;34(1):125-154. 1185098
[20] Bergwerff M, Verberne ME, DeRuiter MC, Poelmann RE, Gittenberger-de Groot 
AC. Neural crest cell contribution to the developing circulatory system: Implications 
for vascular morphology? Circulation Research. 1998;82(2):221-231. DOI: 10.1161/01.
RES.82.2.221
[21] High FA, Zhang M, Proweller A, Tu L, Parmacek MS, Pear WS, Epstein JA. An essential role 
for notch in neural crest during cardiovascular development and smooth muscle differ-
entiation. The Journal of Clinical Investigation. 2007;117(2):353-363. DOI: 10.1172/JCI30070
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
245
[22] Manderfield LJ, Aghajanian H, Engleka KA, Lim LY, Liu F, Jain R, Li L, Olson EN, Epstein 
JA. Hippo signaling is required for notch-dependent smooth muscle differentiation of 
neural crest. Development. 2015;142(17):2962-2971. DOI: 10.1242/dev.125807
[23] Wang X, Astrof S. Neural crest cell-autonomous roles of fibronectin in cardiovascular 
development. Development. 2016;143(1):88-100. DOI: 10.1242/dev.125286
[24] Li J, Zhu X, Chen M, Cheng L, Zhou D, Lu MM, Du K, Epstein JA, Parmacek 
MS. Myocardin-related transcription factor B is required in cardiac neural crest 
for smooth muscle differentiation and cardiovascular development. Proceedings 
of the National Academy of Sciences of the United States of America. 2005;102(25): 
8916-8921. DOI: 10.1073/pnas.0503741102
[25] Xie WB, Li Z, Shi N, Guo X, Tang J, Ju W, Han J, Liu T, Bottinger EP, Chai Y, Jose PA, 
Chen SY. Smad2 and myocardin-related transcription factor B cooperatively regulate 
vascular smooth muscle differentiation from neural crest cells. Circulation Research. 
2013;113(8):e76-e86. DOI: 10.1161/CIRCRESAHA.113.301921
[26] Topouzis S, Majesky MW. Smooth muscle lineage diversity in the chick embryo. Two 
types of aortic smooth muscle cell differ in growth and receptor-mediated transcriptional 
responses to transforming growth factor-beta. Developmental Biology. 1996;178(2): 
430-445. DOI: 10.1006/dbio.1996.0229
[27] Jiao J, Xiong W, Wang L, Yang J, Qiu P, Hirai H, Shao L, Milewicz D, Chen YE, Yang B. 
Differentiation defect in neural crest-derived smooth muscle cells in patients with aor-
topathy associated with bicuspid aortic valves. eBioMedicine. 2016;10:282-290. DOI: 
10.1016/j.ebiom.2016.06.045
[28] Sanchez-Castro M, Eldjouzi H, Charpentier E, Busson PF, Hauet Q, Lindenbaum P, 
Delasalle-Guyomarch B, Baudry A, Pichon O, Pascal C, Lefort B, Bajolle F, Pezard P, 
Schott JJ, Dina C, Redon R, Gournay V, Bonnet D, Le Caignec C. Search for rare copy-
number variants in congenital heart defects identifies novel candidate genes and a poten-
tial role for FOXC1 in patients with coarctation of the aorta. Circulation. Cardiovascular 
Genetics. 2016;9(1):86-94. DOI: 10.1161/CIRCGENETICS.115.001213
[29] Skarie JM, Link BA. FoxC1 is essential for vascular basement membrane integrity 
and hyaloid vessel morphogenesis. Investigative Ophthalmology & Visual Science. 
2009;50(11):5026-5034. DOI: 10.1167/iovs.09-3447
[30] Berry FB, Skarie JM, Mirzayans F, Fortin Y, Hudson TJ, Raymond V, Link BA, Walter 
MA. FOXC1 is required for cell viability and resistance to oxidative stress in the 
eye through the transcriptional regulation of FOXO1A. Human Molecular Genetics. 
2008;17(4):490-505. DOI: 10.1093/hmg/ddm326
[31] Shin YW, Jung KH, Kim JM, Cho YD, Lee ST, Chu K, Kim M, Lee SK, Han MH, Roh 
JK. Echocardiographic evidence of innate aortopathy in the human intracranial aneu-
rysm. PLoS One. 2014;9(6):e100569. DOI: 10.1371/journal.pone.0100569
[32] Yajima I, Colombo S, Puig I, Champeval D, Kumasaka M, Belloir E, Bonaventure J, 
Mark M, Yamamoto H, Taketo MM, Choquet P, Etchevers HC, Beermann F, Delmas V, 
Muscle Cell and Tissue - Current Status of Research Field246
Monassier L, Larue L. A subpopulation of smooth muscle cells, derived from melanocyte-
competent precursors, prevents patent ductus arteriosus. PLoS One. 2013;8(1):e53183. 
DOI: 10.1371/journal.pone.0053183
[33] Grunert M, Dorn C, Schueler M, Dunkel I, Schlesinger J, Mebus S, Alexi-Meskishvili V, 
Perrot A, Wassilew K, Timmermann B, Hetzer R, Berger F, Sperling SR. Rare and private 
variations in neural crest, apoptosis and sarcomere genes define the polygenic back-
ground of isolated tetralogy of Fallot. Human Molecular Genetics. 2014;23(12):3115-3128. 
DOI: 10.1093/hmg/ddu021
[34] Rammeloo LA, DeRuiter MC, van den Akker NM, Wisse LJ, Gittenberger-de Groot 
AC. Development of major aorto-pulmonary collateral arteries in vegf120/120 isoform 
mouse embryos with tetralogy of fallot. Pediatric Cardiology. 2015;36(1):89-95. DOI: 
10.1007/s00246-014-0969-4
[35] Li X, Liu CL, Li XX, Li QC, Ma LM, Liu GL. VEGF gene polymorphisms are associ-
ated with risk of tetralogy of Fallot. Medical Science Monitor. 2015;21:3474-3482. DOI: 
10.12659/MSM.894568
[36] Duran I, Tenney J, Warren CM, Sarukhanov A, Csukasi F, Skalansky M, Iruela-Arispe 
ML, Krakow D. NRP1 haploinsufficiency predisposes to the development of tetralogy of 
Fallot. American Journal of Medical Genetics. Part A. 2018;176(3):649-656. DOI: 10.1002/
ajmg.a.38600
[37] Eldadah ZA, Hamosh A, Biery NJ, Montgomery RA, Duke M, Elkins R, Dietz HC. Familial 
tetralogy of Fallot caused by mutation in the jagged1 gene. Human Molecular Genetics. 
2001;10(2):163-169. PMID: 11152664
[38] Drake CJ, Hungerford JE, Little CD. Morphogenesis of the first blood vessels. Annals 
of the New York Academy of Sciences. 1998;857:155-179. DOI: 10.1111/j.1749-6632.1998.
tb10115
[39] Klein D, Hohn HP, Kleff V, Tilki D, Ergün S. Vascular wall-resident stem cells. Histology 
and Histopathology. 2010;25(5):681-689. DOI: 10.14670/HH-25.681
[40] Majesky MW, Dong XR, Hoglund V, Mahoney WM Jr, Daum G. The adventitia: A 
dynamic interface containing resident progenitor cells. Arteriosclerosis, Thrombosis, 
and Vascular Biology. 2011;31(7):1530-1539. DOI: 10.1161/ATVBAHA.110.221549
[41] Psaltis PJ, Harbuzariu A, Delacroix S, Holroyd EW, Simari RD. Resident vascular progeni-
tor cells--diverse origins, phenotype, and function. Journal of Cardiovascular Translational 
Research. 2011;4(2):161-176. DOI: 10.1007/s12265-010-9248-9
[42] Han YL, Xiao YP, Qi YM, Kang J, Yan CH. Expression of vascular smooth muscle cell 
markers during early stage of embryonic stem cell-derived embryoid bodies differentia-
tion. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2008;24(4):385-390. PMID: 21158132
[43] Rodríguez LV, Alfonso Z, Zhang R, Leung J, Wu B, Ignarro LJ. Clonogenic multipotent 
stem cells in human adipose tissue differentiate into functional smooth muscle cells. 
Proceedings of the National Academy of Sciences of the United States of America. 
2006;103(32):12167-12172. DOI: 10.1073/pnas.0604850103
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
247
[44] Harris LJ, Abdollahi H, Zhang P, McIlhenny S, Tulenko TN, DiMuzio PJ. Differentiation 
of adult stem cells into smooth muscle for vascular tissue engineering. The Journal of 
Surgical Research. 2011;168(2):306-314. DOI: 10.1016/j.jss.2009.08.001
[45] Dong LH, Lv P, Han M. Roles of SM22α in cellular plasticity and vascular diseases. 
Cardiovascular & Hematological Disorders Drug Targets. 2012;12(2):119-125. DOI: 
10.2174/1871529X11202020119
[46] Rashidi N, Tafazzoli-Shadpour M, Haghighipour N, Khani MM. Morphology and 
contractile gene expression of adipose-derived mesenchymal stem cells in response 
to short-term cyclic uniaxial strain and TGF-β1. Biomedizinische Technik. Biomedical 
Engineering. 2017, in press. pii: /j/bmte.ahead-of-print/bmt-2016-0228/bmt-2016-0228.
xml. DOI: 10.1515/bmt-2016-0228
[47] Gong Z, Niklason LE. Small-diameter human vessel wall engineered from bone marrow-
derived mesenchymal stem cells (hMSCs). The FASEB Journal. 2008;22(6):1635-1648. 
DOI: 10.1096/fj.07-087924
[48] Wang C, Yin S, Cen L, Liu Q, Liu W, Cao Y, Cui L. Differentiation of adipose-derived 
stem cells into contractile smooth muscle cells induced by transforming growth fac-
tor-beta1 and bone morphogenetic protein-4. Tissue Engineering. Part A. 2010;16(4): 
1201-1123. DOI: 10.1089/ten.TEA.2009.0303
[49] Xu ZC, Zhang Q, Li H. Human hair follicle stem cell differentiation into contractile 
smooth muscle cells is induced by transforming growth factor-β1 and platelet-derived 
growth factor BB. Molecular Medicine Reports. 2013;8(6):1715-1721. DOI: 10.3892/
mmr.2013.1707
[50] Mesure B, Huber-Villaume S, Menu P, Velot É. Transforming growth factor-beta 1 or 
ascorbic acid are able to differentiate Wharton's jelly mesenchymal stem cells towards 
a smooth muscle phenotype. Bio-medical Materials and Engineering. 2017;28(s1):S101-
S105. DOI: 10.3233/BME-171630
[51] Parizek M, Slepickova Kasalkova N, Bacakova L, Svindrych Z, Slepicka P, Bacakova 
M, Lisa V, Svorcik V. Adhesion, growth, and maturation of vascular smooth muscle 
cells on low-density polyethylene grafted with bioactive substances. BioMed Research 
International. 2013;2013:371430. DOI: 10.1155/2013/371430
[52] Hashemi Gheinani A, Burkhard FC, Rehrauer H, Aquino Fournier C, Monastyrskaya K. 
MicroRNA MiR-199a-5p regulates smooth muscle cell proliferation and morphol-
ogy by targeting WNT2 signaling pathway. The Journal of Biological Chemistry. 
2015;290(11):7067-7086. DOI: 10.1074/jbc.M114.618694
[53] Abcam. Anti-SM22 alpha antibody (ab14106). Available from: http://www.abcam.
com/products?selected.researchAreas=Cardiovascular--Cardiovascular+Markers--
Cell+Markers--Smooth+Muscle+Cells. [Accessed: 2017-02-19]
[54] R & D Systems. Human Caldesmon/CALD1 Antibody. Available from: https://www.
rndsystems.com/products/human-caldesmon-cald1-antibody-767001_mab7569#ds_
image_1 [Accessed: 2017-02-19]
Muscle Cell and Tissue - Current Status of Research Field248
[55] Human Calponin 1 Antibody. Available from: https://www.rndsystems.com/products/
human-calponin-1-antibody-836701_mab7900. [Accessed: 2017-02-19]
[56] Proteintech. Desmin Antibody Rabbit Polyclonal, catalog number: 16520-1-AP. Available 
from: http://www.ptglab.com/products/DES-Antibody-16520-1-AP.htm. [Accessed: 
2017-02-19]
[57] GeneTex. Vinculin antibody [N1N3]. Available from https://www.genetex.com/Vinculin-
antibody-N1N3-GTX113294.html [Accessed: 2017-02-19]
[58] Gabbiani G, Schmid E, Winter S, Chaponnier C, de Ckhastonay C, Vandekerckhove J, 
Weber K, Franke WW. Vascular smooth muscle cells differ from other smooth muscle 
cells: Predominance of vimentin filaments and a specific alpha-type actin. Proceedings 
of the National Academy of Sciences of the United States of America. 1981;78(1):298-302. 
PMID: 7017714
[59] Kiyan Y, Limbourg A, Kiyan R, Tkachuk S, Limbourg FP, Ovsianikov A, Chichkov BN, 
Haller H, Dumler I. Urokinase receptor associates with myocardin to control vascular 
smooth muscle cells phenotype in vascular disease. Arteriosclerosis, Thrombosis, and 
Vascular Biology. 2012;32(1):110-122. DOI: 10.1161/ATVBAHA.111.234369
[60] Pfisterer L, Feldner A, Hecker M, Korff T. Hypertension impairs myocardin func-
tion: A novel mechanism facilitating arterial remodelling. Cardiovascular Research. 
2012;96(1):120-129. DOI: 10.1093/cvr/cvs247
[61] Ohnaka M, Marui A, Yamahara K, Minakata K, Yamazaki K, Kumagai M, Masumoto 
H, Tanaka S, Ikeda T, Sakata R. Effect of microRNA-145 to prevent vein graft disease 
in rabbits by regulation of smooth muscle cell phenotype. The Journal of Thoracic and 
Cardiovascular Surgery. 2014;148(2):676-682.e2. DOI: 10.1016/j.jtcvs.2013.11.054
[62] Crosas-Molist E, Meirelles T, López-Luque J, Serra-Peinado C, Selva J, Caja L, Gorbenko 
Del Blanco D, Uriarte JJ, Bertran E, Mendizábal Y, Hernández V, García-Calero C, 
Busnadiego O, Condom E, Toral D, Castellà M, Forteza A, Navajas D, Sarri E, Rodríguez-
Pascual F, Dietz HC, Fabregat I, Egea G. Vascular smooth muscle cell phenotypic changes 
in patients with Marfan syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 
2015;35(4):960-972. DOI: 10.1161/ATVBAHA.114.304412
[63] Je HD, Sohn UD. SM22alpha is required for agonist-induced regulation of contractil-
ity: Evidence from SM22alpha knockout mice. Molecules and Cells. 2007;23(2):175-181. 
PMID: 17464194
[64] Han M, Dong LH, Zheng B, Shi JH, Wen JK, Cheng Y. Smooth muscle 22 alpha maintains 
the differentiated phenotype of vascular smooth muscle cells by inducing filamentous 
actin bundling. Life Sciences. 2009;84(13-14):394-401. DOI: 10.1016/j.lfs.2008.11.017
[65] Shu YN, Zhang F, Bi W, Dong LH, Zhang DD, Chen R, Lv P, Xie XL, Lin YL, Xue ZY, 
Li H, Miao SB, Zhao LL, Wang H, Han M. SM22α inhibits vascular inflammation via 
stabilization of IκBα in vascular smooth muscle cells. Journal of Molecular and Cellular 
Cardiology. 2015;84:191-199. DOI: 10.1016/j.yjmcc.2015.04.020
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
249
[66] Huber PA. Caldesmon. The International Journal of Biochemistry & Cell Biology. 
1997;29(8-9):1047-1051. DOI: 10.1016/S1357-2725(97)00004-6
[67] D'Addario SF, Morgan M, Talley L, Smoller BR. H-Caldesmon as a specific marker of 
smooth muscle cell differentiation in some soft tissue tumors of the skin. Journal of 
Cutaneous Pathology. 2002;29(7):426-429. DOI: 10.1034/j.1600-0560.2002.290707.x
[68] Winder SJ, Walsh MP. Calponin: Thin filament-linked regulation of smooth muscle con-
traction. Cellular Signalling. 1993;5(6):677-686. PMID: 8130072
[69] el-Mezgueldi M. Calponin. The International Journal of Biochemistry & Cell Biology. 
1996;28(11):1185-1189. DOI: 10.1016/S1357-2725(96)00085-4
[70] Liu R, Jin JP. Calponin isoforms CNN1, CNN2 and CNN3: Regulators for actin cytoskel-
eton functions in smooth muscle and non-muscle cells. Gene. 2016;585(1):143-153. DOI: 
10.1016/j.gene.2016.02.040
[71] Taniguchi S. Suppression of cancer phenotypes through a multifunctional actin-binding 
protein, calponin, that attacks cancer cells and simultaneously protects the host from 
invasion. Cancer Science. 2005;96(11):738-746. DOI: 10.1111/j.1349-7006.2005.00118.x
[72] Hegner B, Weber M, Dragun D, Schulze-Lohoff E. Differential regulation of smooth 
muscle markers in human bone marrow-derived mesenchymal stem cells. Journal of 
Hypertension. 2005;23(6):1191-1202. DOI: 10.1097/01.hjh.0000170382.31085.5d
[73] Mitchell JJ, Reynolds SE, Leslie KO, Low RB, Woodcock-Mitchell J. Smooth muscle cell 
markers in developing rat lung. American Journal of Respiratory Cell and Molecular 
Biology. 1990;3(6):515-523. DOI: 10.1165/ajrcmb/3.6.515
[74] Brinck U, Mirzaie M, Korabiowska M, Meyer T. Expression rate of vinculin isoforms 
in human aortocoronary saphenous vein grafts. International Journal of Cardiology. 
1997;59(2):125-132. DOI: 10.1016/S0167-5273(97)02919-7
[75] Belkin AM, Ornatsky OI, Glukhova MA, Koteliansky VE. Immunolocalization of 
meta-vinculin in human smooth and cardiac muscles. The Journal of Cell Biology. 
1988;107(2):545-553. DOI: 10.1083/jcb.107.2.545
[76] Glukhova MA, Kabakov AE, Belkin AM, Frid MG, Ornatsky OI, Zhidkova NI, 
Koteliansky VE. Meta-vinculin distribution in adult human tissues and cultured cells. 
FEBS Letters. 1986;207(1):139-141. DOI: 10.1016/0014-5793(86)80027-8
[77] Stiebellehner L, Frid MG, Reeves JT, Low RB, Gnanasekharan M, Stenmark KR. Bovine distal 
pulmonary arterial media is composed of a uniform population of well-differentiated smooth 
muscle cells with low proliferative capabilities. American Journal of Physiology. Lung 
Cellular and Molecular Physiology. 2003;285(4):L819-L828. DOI: 10.1152/ajplung.00062.2003
[78] Meyer T, Brink U, Unterberg C, Stöhr S, Kreuzer H, Buchwald AB. Expression of meta-
vinculin in human coronary arteriosclerosis is related to the histological grade of plaque 
formation. Atherosclerosis. 1994;111(1):111-119. DOI: 10.1016/0021-9150(94)90196-1
[79] Shirinsky VP, Birukov KG, Koteliansky VE, Glukhova MA, Spanidis E, Rogers JD, 
Campbell JH, Campbell GR. Density-related expression of caldesmon and vinculin in cul-
tured rabbit aortic smooth muscle cells. Experimental Cell Research. 1991;194(2):186-189. 
DOI: 10.1016/0014-4827(91)90352-U
Muscle Cell and Tissue - Current Status of Research Field250
[80] Wohrley JD, Frid MG, Moiseeva EP, Orton EC, Belknap JK, Stenmark KR. Hypoxia 
selectively induces proliferation in a specific subpopulation of smooth muscle cells in 
the bovine neonatal pulmonary arterial media. The Journal of Clinical Investigation. 
1995;96(1):273-281. DOI: 10.1172/JCI118031
[81] Zanellato AM, Borrione AC, Tonello M, Scannapieco G, Pauletto P, Sartore S. Myosin 
isoform expression and smooth muscle cell heterogeneity in normal and atherosclerotic 
rabbit aorta. Arteriosclerosis. 1990;10(6):996-1009. DOI: 10.1161/01.ATV.10.6.996
[82] Sartore S, Chiavegato A, Franch R, Faggin E, Pauletto P. Myosin gene expression and 
cell phenotypes in vascular smooth muscle during development, in experimental 
models, and in vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology. 
1997;17(7):1210-1215. DOI: 10.1161/01.ATV.17.7.1210
[83] Eddinger TJ, Meer DP. Myosin isoform heterogeneity in single smooth muscle cells. 
Comparative Biochemistry and Physiology. Part B, Biochemistry & Molecular Biology. 
1997;117(1):29-38. PMID: 9180012
[84] Reho JJ, Zheng X, Fisher SA. Smooth muscle contractile diversity in the control of regional 
circulations. American Journal of Physiology. Heart and Circulatory Physiology. 
2014;306(2):H163-H172. DOI: 10.1152/ajpheart.00493.2013
[85] Aikawa M, Sakomura Y, Ueda M, Kimura K, Manabe I, Ishiwata S, Komiyama N, 
Yamaguchi H, Yazaki Y, Nagai R. Redifferentiation of smooth muscle cells after coronary 
angioplasty determined via myosin heavy chain expression. Circulation. 1997;96(1): 
82-90. DOI: 10.1161/01.CIR.96.1.82
[86] van der Loop FT, Schaart G, Timmer ED, Ramaekers FC, van Eys GJ. Smoothelin, a 
novel cytoskeletal protein specific for smooth muscle cells. The Journal of Cell Biology. 
1996;134(2):401-411. DOI: 10.1097/PAI.0b013e31827387c9
[87] Turner SR, MacDonald JA. Novel contributions of the smoothelin-like 1 protein in 
vascular smooth muscle contraction and its potential involvement in myogenic tone. 
Microcirculation. 2014;21(3):249-258. DOI: 10.1111/micc.12108
[88] Ross R, Glomset JA, Kariya B, Harker L. A platelet-dependent serum factor that stimu-
lates the proliferation of arterial smooth muscle cells in vitro. Proceedings of the National 
Academy of Sciences of the United States of America. 1974;71(4):1207-1210. PMID: 4208546
[89] Raines EW. PDGF and cardiovascular disease. Cytokine & Growth Factor Reviews. 
2004;15(4):237-254. DOI: 10.1016/j.cytogfr.2004.03.004
[90] Osada-Oka M, Ikeda T, Imaoka S, Akiba S, Sato T. VEGF-enhanced proliferation under 
hypoxia by an autocrine mechanism in human vascular smooth muscle cells. Journal of 
Atherosclerosis and Thrombosis. 2008;15(1):26-33. DOI: 10.5551/jat.E533
[91] Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atheroscle-
rosis. Acta Medica Indonesiana. 2007;39(2):86-93. PMID: 17933075
[92] Kraemer R, Nguyen H, March KL, Hempstead B. NGF activates similar intracellular sig-
naling pathways in vascular smooth muscle cells as PDGF-BB but elicits different biologi-
cal responses. Arteriosclerosis, Thrombosis, and Vascular Biology. 1999;19(4):1041-1050. 
DOI: 10.1161/01.ATV.19.4.1041
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
251
[93] Ruiz-Torres A. The role of insulin-like growth factor 1 and insulin in ageing and athero-
sclerosis. Novartis Foundation Symposium. 2002;242:143-153; discussion 153-60. PMID: 
11855685
[94] Jensen BA, Chemnitz J, Christensen BC, Junker P, Lorenzen I. D-penicillamine-
induced angiopathy in rats. The effect of high dose D-penicillamine treatment on aor-
tic permeability to albumin and on the ultrastructure of the vessel. Acta Pathologica, 
Microbiologica, et Immunologica Scandinavica. Section A. 1983;91(6):403-411. 6666578
[95] Smani Y, Faivre B, Fries I, Labrude P, Vigneron C. Potential mechanism of dextran-con-
jugated hemoglobin penetration inside arterial wall. Archives des Maladies du Coeur 
et des Vaisseaux. 2006;99(7-8):722-776. PMID: 17061452
[96] Sturge J, Carey N, Davies AH, Powell JT. Fibrin monomer and fibrinopeptide B act 
additively to increase DNA synthesis in smooth muscle cells cultured from human 
saphenous vein. Journal of Vascular Surgery. 2001;33(4):847-853. DOI: 10.1067/mva.2001. 
111984
[97] Isenberg JS, Calzada MJ, Zhou L, Guo N, Lawler J, Wang XQ, Frazier WA, Roberts 
DD. Endogenous thrombospondin-1 is not necessary for proliferation but is permissive 
for vascular smooth muscle cell responses to platelet-derived growth factor. Matrix 
Biology. 2005;24(2):110-123. DOI: 10.1016/j.matbio.2005.01.002
[98] Smiljanic K, Dobutovic B, Obradovic M, Nikolic D, Marche P, Isenovic ER. Involvement 
of the ADAM 12 in thrombin-induced rat's VSMCs proliferation. Current Medicinal 
Chemistry. 2011;18(22):3382-3386. DOI: 10.2174/092986711796504709
[99] Sprague AH, Khalil RA. Inflammatory cytokines in vascular dysfunction and vascular 
disease. Biochemical Pharmacology. 2009;78(6):539-552. DOI: 10.1016/j.bcp.2009.04.029
[100] Sai S, Iwata A, Thomas R, Allen MD. Vascular cell adhesion molecule-1 up-regulation 
and phenotypic modulation of vascular smooth muscle cells predate mononuclear infil-
tration in transplant arteriopathy. The Journal of Thoracic and Cardiovascular Surgery. 
2001;122(3):508-517. DOI: 10.1067/mtc.2001.113601
[101] Hu Y, Xu Q. Adventitial biology: Differentiation and function. Arteriosclerosis, Throm-
bosis, and Vascular Biology. 2011;31(7):1523-1529. DOI: 10.1161/ATVBAHA.110.221176
[102] Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Suenram CA, Rozek MM. Atherosclerosis 
as an inflammatory process. The roles of the monocyte-macrophage. Annals of the 
New York Academy of Sciences. 1985;454:115-120. DOI: 10.1111/j.1749-6632.1985.
tb11849.x
[103] Blum A, Miller HI. The role of inflammation in atherosclerosis. Israel Journal of Medical 
Sciences. 1996;32(11):1059-1065. 8960073
[104] Maxova H, Novotna J, Vajner L, Tomasova H, Vytasek R, Vizek M, Bacakova L, Valouskova V, 
Eliasova T, Herget J. In vitro hypoxia increases production of matrix metalloproteinases 
and tryptase in isolated rat lung mast cells. Physiological Research. 2008;57:903-910. PMID: 
18052689
Muscle Cell and Tissue - Current Status of Research Field252
[105] Maxova H, Bacakova L, Lisa V, Novotna J, Tomasova H, Vizek M, Herget J. Production 
of proteolytic enzymes in mast cells, fibroblasts, vascular smooth muscle and endo-
thelial cells cultivated under normoxic or hypoxic conditions. Physiological Research. 
2010;59:711-719. PMID: 20406036
[106] Sung HJ, Eskin SG, Sakurai Y, Yee A, Kataoka N, McIntire LV. Oxidative stress 
produced with cell migration increases synthetic phenotype of vascular smooth 
muscle cells. Annals of Biomedical Engineering. 2005;33(11):1546-1554. DOI: 10.1007/
s10439-005-7545-2
[107] Takahashi K, Takeya M, Sakashita N. Multifunctional roles of macrophages in the 
development and progression of atherosclerosis in humans and experimental animals. 
Medical Electron Microscopy. 2002;35(4):179-203. DOI: 10.1007/s007950200023
[108] Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic 
plaques. Proceedings of the National Academy of Sciences of the United States of 
America. 1973;70(6):1753-1756. PMID: 4515934
[109] Pearson TA, Kramer EC, Solez K, Heptinstall RH. The human atherosclerotic plaque. 
The American Journal of Pathology. 1977;86(3):657-664. PMID: 842615
[110] Sjölund M, Madsen K, von der Mark K, Thyberg J. Phenotype modulation in primary 
cultures of smooth-muscle cells from rat aorta. Synthesis of collagen and elastin. Differe-
ntiation. 1986;32(2):173-180. DOI: 10.1111/j.1432-0436.1986.tb00570.x
[111] Steitz SA, Speer MY, Curinga G, Yang HY, Haynes P, Aebersold R, Schinke T, Karsenty 
G, Giachelli CM. Smooth muscle cell phenotypic transition associated with calcifica-
tion: Upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. 
Circulation Research. 2001;89(12):1147-1154. DOI: 10.1161/hh2401.101070
[112] Trion A, van der Laarse A. Vascular smooth muscle cells and calcification in atheroscle-
rosis. American Heart Journal. 2004;147(5):808-814. DOI: 10.1016/j.ahj.2003.10.047
[113] Lin ME, Chen TM, Wallingford MC, Nguyen NB, Yamada S, Sawangmake C, Zhang J, 
Speer MY, Giachelli CM. Runx2 deletion in smooth muscle cells inhibits vascular 
osteochondrogenesis and calcification but not atherosclerotic lesion formation. Cardio-
vascular Research. 2016. pii: cvw205. DOI: 10.1093/cvr/cvw205
[114] Owens GK. Control of hypertrophic versus hyperplastic growth of vascular smooth 
muscle cells. The American Journal of Physiology. 1989;257(6 Pt 2):H1755-H1765. DOI: 
10.1152/ajpheart.1989.257.6.H1755
[115] Hixon ML, Gualberto A. Vascular smooth muscle polyploidization--from mitotic check-
points to hypertension. Cell Cycle. 2003;2(2):105-110. DOI: 10.4161/cc.2.2.341
[116] Nagata Y, Jones MR, Nguyen HG, McCrann DJ, St Hilaire C, Schreiber BM, Hashimoto 
A, Inagaki M, Earnshaw WC, Todokoro K, Ravid K. Vascular smooth muscle cell poly-
ploidization involves changes in chromosome passenger proteins and an endomitotic 
cell cycle. Experimental Cell Research. 2005;305(2):277-291. DOI: 10.1016/j.yexcr.2004. 
12.028
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
253
[117] Bacakova L, Pellicciari C, Bottone MG, Lisa V, Mares V. A sex-related difference in the 
hypertrophic versus hyperplastic response of vascular smooth muscle cells to repeated 
passaging in culture. Histology and Histopathology. 2001;16(3):675-684. PMID: 11510955
[118] McCrann DJ, Yang D, Chen H, Carroll S, Ravid K. Upregulation of Nox4 in the aging 
vasculature and its association with smooth muscle cell polyploidy. Cell Cycle. 2009;8(6): 
902-908. DOI: 10.4161/cc.8.6.7900
[119] Blaes N, Bourdillon MC, Daniel-Lamaziere JM, Michaille JJ, Andujar M, Covacho 
C. Isolation of two morphologically distinct cell lines from rat arterial smooth muscle 
expressing high tumorigenic potentials. In Vitro Cellular & Developmental Biology. 
1991;27A(9):725-734. PMID: 1917792
[120] Papageorgiou P, Morgan KG. Intracellular free Ca2+ is elevated in hypertrophic aortic 
muscle from hypertensive rats. The American Journal of Physiology. 1991;260(2 Pt 2): 
H507-H515. DOI: 10.1152/ajpheart.1991.260.2.H507
[121] Jernigan NL, Resta TC, Gonzalez Bosc LV. Altered redox balance in the development of 
chronic hypoxia-induced pulmonary hypertension. Advances in Experimental Medicine 
and Biology. 2017;967:83-103. DOI: 10.1007/978-3-319-63245-2_7
[122] Orton EC, LaRue SM, Ensley B, Stenmark K. Bromodeoxyuridine labeling and DNA 
content of pulmonary arterial medial cells from hypoxia-exposed and nonexposed 
healthy calves. American Journal of Veterinary Research. 1992;53(10):1925-1930. PMID: 
1456542
[123] Herget J, Novotna J, Bibova J, Povysilova V, Vankova M, Hampl V. Metalloproteinase 
inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic 
rats. American Journal of Physiology. Lung Cellular and Molecular Physiology. 
2003;285(1):L199-L208. DOI: 10.1152/ajplung.00167.2002
[124] Irwin DC, Baek JH, Hassell K, Nuss R, Eigenberger P, Lisk C, Loomis Z, Maltzahn J, 
Stenmark KR, Nozik-Grayck E, Buehler PW. Hemoglobin-induced lung vascular oxida-
tion, inflammation, and remodeling contribute to the progression of hypoxic pulmonary 
hypertension and is attenuated in rats with repeated-dose haptoglobin administration. 
Free Radical Biology & Medicine. 2015;82:50-62. DOI: 10.1016/j.freeradbiomed.2015.01.012
[125] Morris CR. Asthma management: Reinventing the wheel in sickle cell disease. American 
Journal of Hematology. 2009;84(4):234-241. DOI: 10.1002/ajh.21359
[126] Racanelli AC, Kikkers SA, Choi AMK, Cloonan SM. Autophagy and inflammation in 
chronic respiratory disease. Autophagy. 2017:1-12. DOI: 10.1080/15548627.2017.1389823
[127] Dournes G, Laurent F, Coste F, Dromer C, Blanchard E, Picard F, Baldacci F, Montaudon 
M, Girodet PO, Marthan R, Berger P. Computed tomographic measurement of air-
way remodeling and emphysema in advanced chronic obstructive pulmonary disease. 
Correlation with pulmonary hypertension. American Journal of Respiratory and Critical 
Care Medicine. 2015;191(1):63-70. DOI: 10.1164/rccm.201408-1423OC
[128] Fein DG, Zaidi AN, Sulica R. Pulmonary hypertension due to common respiratory 
conditions: Classification, evaluation and management strategies. Journal of Clinical 
Medicine. 2016;5(9):E75. DOI: 10.3390/jcm5090075
Muscle Cell and Tissue - Current Status of Research Field254
[129] Quarck R, Wynants M, Ronisz A, Sepulveda MR, Wuytack F, Van Raemdonck D, Meyns 
B, Delcroix M. Characterization of proximal pulmonary arterial cells from chronic throm-
boembolic pulmonary hypertension patients. Respiratory Research. 2012;13:27. DOI: 
10.1186/1465-9921-13-27
[130] Chen L, Li YS, Cui J, Ning JN, Wang GS, Qian GS, Lu KZ, Yi B. MiR-206 controls the 
phenotypic modulation of pulmonary arterial smooth muscle cells induced by serum 
from rats with hepatopulmonary syndrome by regulating the target gene, annexin A2. 
Cellular Physiology and Biochemistry. 2014;34(5):1768-1779. DOI: 10.1159/000366377
[131] Hampl V, Herget J. Role of nitric oxide in the pathogenesis of chronic pulmonary hyper-
tension. Physiological Reviews. 2000;80(4):1337-1372. DOI: 10.1152/physrev.2000.80.4. 
1337
[132] Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: 
Cellular and molecular mechanisms. Circulation Research. 2006;99(7):675-691. DOI: 
10.1161/01.RES.0000243584.45145.3f
[133] Stenmark KR, Frid MG, Graham BB, Tuder RM. Dynamic and diverse changes in the 
functional properties of vascular smooth muscle cells in pulmonary hypertension. 
Cardiovascular Research. 2018;114(4):551-564. DOI: 10.1093/cvr/cvy004
[134] Gui Y, He GH, Walsh MP, Zheng XL. Predisposition to tetraploidy in pulmonary vascular 
smooth muscle cells derived from the Eker rats. American Journal of Physiology. Lung 
Cellular and Molecular Physiology. 2007;293(3):L702-L711. DOI: 10.1152/ajplung.00016.2007
[135] Stenmark KR, Tuder RM, El Kasmi KC. Metabolic reprogramming and inflammation act 
in concert to control vascular remodeling in hypoxic pulmonary hypertension. Journal of 
Applied Physiology (1985). 2015;119(10):1164-1172. DOI: 10.1152/japplphysiol.00283.2015
[136] Stenmark KR, Bouchey D, Nemenoff R, Dempsey EC, Das M. Hypoxia-induced pul-
monary vascular remodeling: Contribution of the adventitial fibroblasts. Physiological 
Research. 2000;49(5):503-517. PMID: 11191356
[137] Leroux-Berger M, Queguiner I, Maciel TT, Ho A, Relaix F, Kempf H. Pathologic cal-
cification of adult vascular smooth muscle cells differs on their crest or mesodermal 
embryonic origin. Journal of Bone and Mineral Research. 2011;26(7):1543-1553. DOI: 
10.1002/jbmr.382
[138] Hsu S, Chu JS, Chen FF, Wang A, Li S. Effects of fluid shear stress on a distinct popula-
tion of vascular smooth muscle cells. Cellular and Molecular Bioengineering. 2011;4(4): 
627-636. DOI: 10.1007/s12195-011-0205-8
[139] Gadson PF Jr, Rossignol C, McCoy J, Rosenquist TH. Expression of elastin, smooth 
muscle alpha-actin, and c-Jun as a function of the embryonic lineage of vascular smooth 
muscle cells. In Vitro Cellular & Developmental Biology. Animal. 1993;29A(10):773-781. 
PMID: 8118612
[140] Yamamoto M, Yamamoto K, Noumura T. Type I collagen promotes modulation of cul-
tured rabbit arterial smooth muscle cells from a contractile to a synthetic phenotype. 
Experimental Cell Research. 1993;204(1):121-129. DOI: 10.1006/excr.1993.1016
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
255
[141] Karnik SK, Brooke BS, Bayes-Genis A, Sorensen L, Wythe JD, Schwartz RS, Keating 
MT, Li DY. A critical role for elastin signaling in vascular morphogenesis and disease. 
Development. 2003;130(2):411-423. DOI: 10.1242/dev.00223
[142] Lange M, Fujikawa T, Koulova A, Kang S, Griffin MJ, Lassaletta AD, Erat A, Tobiasch 
E, Bianchi C, Elmadhun N, Sellke FW, Usheva A. Arterial territory-specific phosphory-
lated retinoblastoma protein species and CDK2 promote differences in the vascular 
smooth muscle cell response to mitogens. Cell Cycle. 2014;13(2):315-323. DOI: 10.4161/
cc.27056
[143] Faries PL, Rohan DI, Wyers MC, Marin ML, Hollier LH, Quist WC, LoGerfo FW. Vascular 
smooth muscle cells derived from atherosclerotic human arteries exhibit greater adhe-
sion, migration, and proliferation than venous cells. The Journal of Surgical Research. 
2002;104(1):22-28. DOI: 10.1006/jsre.2002.6399
[144] Xiao Y, Huang Z, Yin H, Zhang H, Wang S. Desmuslin gene knockdown causes altered 
expression of phenotype markers and differentiation of saphenous vein smooth muscle 
cells. Journal of Vascular Surgery. 2010;52(3):684-690. DOI: 10.1016/j.jvs.2010.03.069
[145] Filova E, Parizek M, Olsovska J, Kamenik Z, Brynda E, Riedel T, Vandrovcova M, Lisa V, 
Machova L, Skalsky I, Szarszoi O, Suchy T, Bacakova L. Perivascular sirolimus-delivery 
system. International Journal of Pharmaceutics. 2011;404(1-2):94-101. DOI: 10.1016/j.
ijpharm.2010.11.005
[146] Skalský I, Szárszoi O, Filová E, Pařízek M, Lytvynets A, Malušková J, Lodererová A, 
Brynda E, Lisá V, Burdíková Z, Capek M, Pirk J, Bačáková L. A perivascular system 
releasing sirolimus prevented intimal hyperplasia in a rabbit model in a medium-term 
study. International Journal of Pharmaceutics. 2012;427(2):311-319. DOI: 10.1016/j.
ijpharm.2012.02.023
[147] Durante W. Role of arginase in vessel wall remodeling. Frontiers in Immunology. 
2013;4:111. DOI: 10.3389/fimmu.2013.00111
[148] Imegwu OJ, Entersz I, Graham AM, Nackman GB. Heterotypic smooth muscle cell/
endothelial cell interactions differ between species. The Journal of Surgical Research. 
2001;98(2):85-88. DOI: 10.1006/jsre.2001.6165
[149] Rosen EM, Goldberg ID, Shapiro HM, Levenson SE, Halpin PA, Faraggi D. Strain and 
site dependence of polyploidization of cultured rat smooth muscle. Journal of Cellular 
Physiology. 1986;128(2):337-344. DOI: 10.1002/jcp.1041280228
[150] Bacakova L, Kunes J. Gender differences in growth of vascular smooth muscle cells iso-
lated from hypertensive and normotensive rats. Clinical and Experimental Hypertension. 
2000;22(1):33-44. PMID: 10685723
[151] Bacakova L, Mares V. Cell kinetics of aortic smooth muscle cells in long-term cultures pre-
pared from rats raised under conventional and SPF conditions. Physiological Research. 
1995;44(6):389-398. PMID: 8798274
[152] Thyberg J. Differentiated properties and proliferation of arterial smooth muscle cells in 
culture. International Review of Cytology. 1996;169:183-265. PMID: 8843655
Muscle Cell and Tissue - Current Status of Research Field256
[153] van Neck JW, van Berkel PH, Telleman P, Steijns LS, Onnekink C, Bloemers HP. Effect 
of ploidy on transcription levels in cultured rat aortic smooth muscle cells. FEBS Letters. 
1992;297(1-2):189-195. DOI: 10.1016/0014-5793(92)80358-N
[154] Werstiuk ES, Lee RM. Vascular beta-adrenoceptor function in hypertension and in 
ageing. Canadian Journal of Physiology and Pharmacology. 2000;78(6):433-452. PMID: 
10914632
[155] Li M, Fukagawa NK. Age-related changes in redox signaling and VSMC function. 
Antioxidants & Redox Signaling. 2010;12(5):641-655. DOI: 10.1089/ars.2009.2854
[156] Martín-Pardillos A, Sorribas V. Effects of donor age and proliferative aging on the 
phenotype stability of rat aortic smooth muscle cells. Physiological Reports. 2015;3(11). 
DOI: 10.14814/phy2.12626
[157] Uryga AK, Bennett MR. Ageing induced vascular smooth muscle cell senescence in ath-
erosclerosis. The Journal of Physiology. 2016;594(8):2115-2124. DOI: 10.1113/JP270923
[158] Travo P, Barrett G, Burnstock G. Differences in proliferation of primary cultures of vas-
cular smooth muscle cells taken from male and female rats. Blood Vessels. 1980;17(2): 
110-116. PMID: 7362876
[159] Bacakova L, Lisa V, Pellicciari C, Mares V, Bottone MG, Kocourek F. Sex related dif-
ferences in the adhesion, migration, and growth of rat aortic smooth muscle cells in 
culture. In Vitro Cellular & Developmental Biology. Animal. 1997a;33(6):410-413. DOI: 
10.1007/s11626-997-0055-9
[160] Bacakova L, Mares V, Lisa V. Gender-related differences in adhesion, growth and dif-
ferentiation of vascular smooth muscle cells are enhanced in serum-deprived cultures. 
Cell Biology International. 1999;23(9):643-648. DOI: 10.1006/cbir.1999.0417
[161] Bacakova L, Pellicciari C, Bottone MG, Lisa V, Mares V. A sex-related difference in the 
hypertrophic versus hyperplastic response of vascular smooth muscle cells to repeated 
passaging in culture. Histology and Histopathology. 2001;16(3):675-684. PMID: 11510955
[162] Bacakova L, Mares V, Lisa V, Kocourek F. Sex-dependent differences in growth and 
morphology of cultured vascular smooth muscle cells from newborn rats. Physiological 
Research. 1997b;46(5):403-406. PMID: 9728488
[163] Ely DL, Falvo J, Dunphy G, Caplea A, Salisbury R, Turner M. The spontaneously hyper-
tensive rat Y chromosome produces an early testosterone rise in normotensive rats. 
Journal of Hypertension. 1994;12(7):769-774. PMID: 7963505
[164] Ely D, Caplea A, Dunphy G, Daneshvar H, Turner M, Milsted A, Takiyyudin M. 
Spontaneously hypertensive rat Y chromosome increases indexes of sympathetic ner-
vous system activity. Hypertension. 1997;29(2):613-618. DOI: 10.1161/01.HYP.29.2.613
The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels
http://dx.doi.org/10.5772/intechopen.77115
257

